Post by Novartis

This year marks 25 years since the first tyrosine kinase inhibitor (TKI) transformed the treatment paradigm for chronic myeloid leukemia (CML) and cancer care overall. As we reflect on how far CML care has come, we are joining the hematology community at the European Hematology Association (EHA) Congress in Stockholm to continue the conversation on the needs of people living with CML today, and the possibilities still to come. Follow the live conversation at #EHA2026, and read more about the journey in managing CML here: https://lnkd.in/eJxQBTyY #CML #ReimaginingMedicine